1Rangel LB, Agarwall R, D' Souza T, et al. Tight junction proteins claudin-3 and claudin-4 are frequently over-expressed in ovarian cancer but not in ovarian cystadenomas [J]. Int J Clin Cancer Res,2003,9: 2567-2575.
2Santin AD, Zhan Feng-huang, Bellone S, et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: dentification of candidate molecular markers for ovarian cancer diagnosis and therapy [J]. Cancer,2004,112:14-25.
3Santin AD, Canfi S, Bellone S, et al. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C. B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin [J]. Cancer Res,2005,65 (10) : 4334-4342.
4Zhou Jun, Liu Min, Luthra R, et al. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice [J ]. Cancer Chemother Pharmacol, 2005,55(5) :461-465.
5Mozzetti S, Ferlini C, Concolino P, et al. Class Ⅲ betatubulin overexpression is a prominent mechanism of paditaxel resistance in ovarian cancer patients [J]. Clin Cancer Res,2005,11(1): 298-305.
6Lee S, Choi EJ, Jin C, et al. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line [J ]. Gynecol Oncol, 2005, 97 ( 1 ) : 26-34.
7Park SJ,Armstrong S, Kim CH, et al. Lack of EGF receptor contributes to drug sensitivity of human germline cells [J]. Br J Cancer,2005,92(2) : 334-341.
8Abuharbeid S, Apel J, Zugrnaier G, et al. Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells [J ]. Naunyn Schmiedebergs Arch Pharmacol,2005,371(2) : 141-151.
9Nakada S,Aoki D, Ohie S, et al. Chemosensitivity testing of ovarian cancer using the histoculture drug response assay: sensitivity to cisplatin and clinical response[J]. Int J Gynecol Cancer,2005,15(3) : 445-452.
10Steller MD, Shaw TJ, Vanderhyden BC, et al. Inhibin resistance is associated with aggressive tumorigenicity of ovarian cancer cells [J]. Mol Cancer Res, 2005,3 ( 1 ) :50-61.
